A Study to Investigate the Prevalence of Single Nucleotide Polymorphisms (Snps) in, Cyp2c19, Hdac9, Apoe, Pmf1 and Pitx2 in Patients with Hemorrhagic or Ischemic Stroke

Abstract

In present study, 46% of recurrent stroke patients had clopidogrel resistance, our data is comparable to  western data where the prevalence rate is 5 -44%. This data shows that it is imperative to check the prevalence of clopidogrel resistance in new onset stroke, recurrent stroke as well as those patients who are on dual antiplatelet drug therapy for cardiac disease, but develop atherothrombotic stroke. The results of the study are in congruence with the current FDA guidelines which recommend routine testing of clopidogrel resistance. The present study focuses on HDAC9 gene in  all  patients  and found that three genotype polymorphisms are  present, namely CC, CT, TT. Studies have shown HDAC9 gene to be significantly associated with  progressive  atherosclerosis and higher incidence of strokes. HDAC9 gene was compared to MRA study with mild, moderate and severe disease. The CC genome polymorphism showed high rates of atherosclerosis disease on MRA when compared to CT/ TT polymorphism groups. From this study we infer that CC  genotype  is  more prevalent, and CC group genotype has higher prevalence of risk factors.